
Frexalimab Phase 2 Results: Reduction of Key Biomarker of Nerve Cell Damage in Relapsing MS
Sanofi’s CD40L monoclonal antibody, frexalimab, has demonstrated promising results in reducing a key biomarker associated with nerve cell damage in patients with relapsing multiple sclerosis (MS), suggesting potential benefits in…













